A detailed history of Susquehanna International Group, LLP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 234,866 shares of BCRX stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
234,866
Previous 276,351 15.01%
Holding current value
$1.78 Million
Previous $1.71 Million 4.51%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $265,918 - $360,504
-41,485 Reduced 15.01%
234,866 $1.78 Million
Q2 2024

Aug 15, 2024

SELL
$4.13 - $6.79 $3.47 Million - $5.71 Million
-840,606 Reduced 75.26%
276,351 $1.71 Million
Q1 2024

May 07, 2024

BUY
$4.89 - $7.65 $3.82 Million - $5.98 Million
782,090 Added 233.55%
1,116,957 $5.67 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $75,945 - $103,242
15,250 Added 4.77%
334,867 $2.01 Million
Q3 2023

Nov 14, 2023

SELL
$6.71 - $7.92 $662,035 - $781,418
-98,664 Reduced 23.59%
319,617 $2.26 Million
Q2 2023

Aug 11, 2023

SELL
$6.96 - $8.81 $1.06 Million - $1.34 Million
-152,426 Reduced 26.71%
418,281 $2.94 Million
Q1 2023

May 16, 2023

BUY
$7.94 - $11.84 $289,547 - $431,769
36,467 Added 6.83%
570,707 $4.76 Million
Q4 2022

Feb 14, 2023

SELL
$10.5 - $14.2 $4.34 Million - $5.87 Million
-413,189 Reduced 43.61%
534,240 $6.13 Million
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $808,678 - $1.11 Million
-74,947 Reduced 7.33%
947,429 $11.9 Million
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $1.72 Million - $3.89 Million
-217,375 Reduced 17.53%
1,022,376 $10.8 Million
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $8.74 Million - $14.9 Million
-756,233 Reduced 37.89%
1,239,751 $20.2 Million
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $2.95 Million - $4.08 Million
263,742 Added 15.23%
1,995,984 $27.6 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $1.28 Million - $1.59 Million
90,292 Added 5.5%
1,732,242 $24.9 Million
Q2 2021

Aug 11, 2021

SELL
$9.5 - $17.24 $4.3 Million - $7.8 Million
-452,495 Reduced 21.6%
1,641,950 $26 Million
Q1 2021

May 17, 2021

BUY
$7.37 - $13.61 $371,904 - $686,787
50,462 Added 2.47%
2,094,445 $21.3 Million
Q4 2020

Feb 16, 2021

BUY
$3.37 - $8.61 $2.45 Million - $6.26 Million
726,520 Added 55.15%
2,043,983 $15.2 Million
Q3 2020

Nov 16, 2020

SELL
$3.43 - $5.53 $351,657 - $566,957
-102,524 Reduced 7.22%
1,317,463 $4.53 Million
Q2 2020

Aug 14, 2020

BUY
$1.9 - $5.61 $1.96 Million - $5.78 Million
1,029,620 Added 263.76%
1,419,987 $6.77 Million
Q1 2020

May 15, 2020

BUY
$1.6 - $4.11 $446,147 - $1.15 Million
278,842 Added 250.03%
390,367 $781,000
Q4 2019

Feb 14, 2020

SELL
$1.59 - $3.45 $53,047 - $115,102
-33,363 Reduced 23.03%
111,525 $385,000
Q3 2019

Nov 14, 2019

SELL
$2.5 - $3.73 $774,527 - $1.16 Million
-309,811 Reduced 68.14%
144,888 $415,000
Q2 2019

Aug 16, 2019

BUY
$2.91 - $9.15 $111,403 - $350,289
38,283 Added 9.19%
454,699 $1.72 Million
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $1.1 Million - $3.45 Million
377,493 Added 969.85%
416,416 $1.58 Million
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $159,584 - $232,370
38,923
38,923 $204,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.